New test aims to predict cancer return after bone marrow transplant

NCT ID NCT06569095

First seen Feb 25, 2026

Summary

This study looks at whether detecting MDS stem cells using a special lab test (flow cytometry) can predict if the disease will come back after a stem cell transplant. Researchers will follow 163 MDS patients for one year after transplant to see if this method is better than current monitoring. The goal is to improve early detection of relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, China

    Contact Email: •••••@•••••

  • Wuhan TongJi Hospital

    RECRUITING

    Wuhan, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a better way to predict relapse in MDS patients after transplant, helping doctors intervene earlier.

What could go wrong

This is an observational study, not a treatment trial. It may not show a clear benefit, and results may not apply to all MDS patients.

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome myelodysplastic syndrome with excess blasts Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.